Before joining ImmunoGen, Mr Perry was CFO of Elixir Pharmaceuticals, where he was extensively involved in partnering and fundraising activities. Prior to Elixir, he was CFO of Domantis, an antibody-related therapeutics company.
Daniel Junius, president and CEO of ImmunoGen, said: “Greg is an excellent addition to our management team, as he has extensive financial expertise and an impressive record of building value at healthcare-focused companies. We believe Greg’s depth of experience is particularly valuable in light of our growing portfolio of advancing anticancer compounds.”